Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.

Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, R Bernard G, B Ekstrom L, Lancaster WJ, Denny JC
Drug Saf. 2018 41 (3): 303-311

PMID: 29185237 · PMCID: PMC5828879 · DOI:10.1007/s40264-017-0616-0

MeSH Terms (13)

Cholesterol, LDL Enzyme Inhibitors Female Genotype Humans Hypercholesterolemia Male PCSK9 Inhibitors Phenotype Polymorphism, Single Nucleotide Product Surveillance, Postmarketing Risk Factors Spinal Dysraphism

Connections (2)

This publication is referenced by other Labnodes entities: